Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Clinical Trial Data

Oruka Therapeutics Shares Skyrocket 30% in 10 Days Since Other

Oruka Therapeutics (ORKA) Reports 61% Complete Skin Clearance in Phase 2b Trial

+30.70% in 10 days $80.15 when we broke this story → $104.76 at 9:36 AM ET, 9 Nov 2026

Oruka Therapeutics announced that its Phase 2b EVERLAST-B trial for ORKA-001 met its primary endpoint in patients with moderate-to-severe plaque psoriasis. The data showed high rates of complete skin clearance and a safety profile consistent with the IL-23p19 class, supporting a Phase 3 initiation in early 2027.

People, scientist, microscope, white. Stock photo illustrating Oruka Therapeutics' other story.
Oruka Therapeutics, Inc. · Healthcare · Photo: PublicDomainPictures / Pixabay

Key highlights

  • 61% of patients in the 600 mg high-dose group achieved PASI 100 at Week 16 vs 0% for placebo
  • High-dose secondary endpoints reached 86% for both PASI 90 and IGA 0/1 clearance
  • Safety data showed 39% treatment-emergent adverse events in the high-dose group
  • Company plans to initiate Phase 3 clinical trials for ORKA-001 in the first half of 2027
  • Cash reserves of $1.1 billion expected to fund operations through the BLA filing for ORKA-001

Clinical Efficacy and Safety Results

Oruka Therapeutics reported that its Phase 2b EVERLAST-B trial met its primary endpoint, with 61% of patients in the 600 mg ORKA-001 group achieving PASI 100 at Week 16. The double-blind, placebo-controlled study involved 187 patients with moderate-to-severe plaque psoriasis across sites in the U.S., Canada, and Europe. Secondary efficacy endpoints indicated that 86% of high-dose patients reached PASI 90 and IGA 0/1 scores. Safety data remained consistent with the IL-23p19 inhibitor class, as 39% of patients in the high-dose cohort reported treatment-emergent adverse events compared to 43% in the placebo group.

Upcoming Pipeline Milestones

  • Initiation of Phase 3 trials for ORKA-001 in moderate-to-severe psoriasis expected in 1H 2027
  • Full 52-week data for the EVERLAST-A Phase 2a trial on track for December 2026
  • ORKA-002 16-week results from the ORCA-SURGE Phase 2 trial expected in 1Q 2027
  • Ongoing assessment of long-term durability and once-yearly maintenance dosing through Week 100
Oruka Therapeutics, Inc. share price · last month
Line chart of Oruka Therapeutics, Inc.'s share price over the last month, from $74.48 on 19 Oct → $99.24 on 16 Nov; our story on 26 Oct at $80.15.

Up 23.8% since our story on 26 Oct: $80.15 when we broke it → $99.24 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$74.48
20 Oct$79.09
21 Oct$79.92
22 Oct$81.15
23 Oct$80.15
26 Oct$90.33
27 Oct$95.81
28 Oct$95.97
29 Oct$96.65
30 Oct$96.87
2 Nov$95.43
3 Nov$99.55
4 Nov$101.41
5 Nov$96.02
6 Nov$102.86
9 Nov$104.56
10 Nov$109.50
11 Nov$107.17
12 Nov$104.99
13 Nov$105.35
16 Nov$99.24

Clinical Development Significance

“These results further solidify our confidence that ORKA-001 could become the preferred medicine for psoriasis, with high rates of complete skin clearance, a favorable safety profile, and potential for dosing once to twice per year.”

Joana Goncalves, MBChB, Chief Medical Officer, Oruka Therapeutics

Financial and Industry Context

As a clinical-stage biotechnology firm, Oruka currently maintains no commercial revenue or order backlog. However, the company holds a strong liquidity position following an upsized $700.4 million public offering completed in April 2026. Management has projected that its current cash and marketable securities, totaling approximately $1.1 billion, will be sufficient to fund operations through the eventual Biologics License Application filing for ORKA-001. The company's market capitalization stands at $5.31 billion as it advances a pipeline of half-life extended biologics designed for less frequent maintenance dosing than existing standard-of-care treatments.

Earlier announcements by Oruka Therapeutics, Inc.
DateAnnouncementAmount
23 Sep 2026Positive Week 28 results for ORKA-001 from the Phase 2a EVERLAST-A trial in moderate-to-severe plaque psoriasisSource: globenewswire.com–
10 Aug 2026Second quarter 2026 financial results and corporate updateSource: ir.orukatx.com–
13 May 2026First quarter 2026 financial results and corporate updateSource: ir.orukatx.com–
28 Apr 2026Pricing of upsized underwritten public offering of 9,660,000 common sharesSource: ir.orukatx.com$700.4 Million
27 Apr 2026Positive Week 16 interim results for ORKA-001 from the Phase 2a EVERLAST-A trialSource: ir.orukatx.com–

Management commentary

“The potential for these effects to be long lasting, with just one or two doses a year, would be a paradigm shift in moderate-to-severe psoriasis management, allowing for the trifecta of clear skin, convenience, and excellent safety that would further elevate the standard of care we can offer our patients.”

Joel Gelfand, MD, Lead Investigator for EVERLAST-B
Oruka Therapeutics, Inc. · financial snapshot
Share price$80.15
Market cap$5.3B
1-month price change-10.88%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Oruka Therapeutics, Inc. announcing Week 16 results from its Phase 2b EVERLAST-B clinical trial.

Read the filing ↗

Track Oruka Therapeutics, Inc. live

Get the next Oruka Therapeutics, Inc. SEC filing seconds after it lands.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.